LEADER 01043nam0-2200337---450- 001 990009808740403321 005 20140115111429.0 010 $a978-88-204-2189-2 035 $a000980874 035 $aFED01000980874 035 $a(Aleph)000980874FED01 035 $a000980874 100 $a20140115d2013----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $ay-------001yy 200 1 $aTra diritti umani e distensione$el'amministrazione Carter e il dissenso in URSS$fUmberto Tulli$gprefazione di Mario Del Pero 210 $aMilano$cFrancoAngeli$d2013 215 $a255 p.$d23 cm 225 1 $aStoria internazionale dell'età contemporanea$v14 610 0 $aCarter, Jimmy$aPolitica estera 676 $a327.73047$v22$zita 700 1$aTulli,$bUmberto$0521810 702 1$aDel Pero,$bMario 801 0$aIT$bUNINA$gREICAT$2UNIMARC 901 $aBK 912 $a990009808740403321 952 $aCollez. 2174 (14)$b51215$fFSPBC 959 $aFSPBC 996 $aTra diritti umani e distensione$9838015 997 $aUNINA LEADER 04684nam 2200613 450 001 9910830911403321 005 20230130141936.0 010 $a1-68367-340-9 010 $a1-68367-098-1 010 $a1-55581-741-6 035 $a(CKB)3710000000376186 035 $a(EBL)3563369 035 $a(SSID)ssj0001518274 035 $a(PQKBManifestationID)12621511 035 $a(PQKBTitleCode)TC0001518274 035 $a(PQKBWorkID)11509719 035 $a(PQKB)10329051 035 $a(MiAaPQ)EBC3563369 035 $a(PPN)19286100X 035 $a(EXLCZ)993710000000376186 100 $a20150627h20152015 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAntibodies for infectious diseases /$fedited by James E. Crowe, Jr., Diana Boraschi and Rino Rappuoli 210 1$aWashington, District of Columbia :$cASM Press,$d2015. 210 4$d©2015 215 $a1 online resource (476 p.) 300 $aDescription based upon print version of record. 311 $a1-55581-735-1 320 $aIncludes bibliographical references and index. 327 $a""Cover ""; ""Half Title ""; ""Title Page ""; ""Copyright ""; ""Contents ""; ""Contr ibutors ""; ""Preface ""; ""INTRODUCTION""; ""Chapter 1: History and Practice: Antibodies in Infectious Diseases""; ""HISTORICAL PERSPECTIVE""; ""INTRODUCTION TO ANTIBODIES""; ""METHODS AND PLATFORMS FOR GENERATING ANTIBODIES""; ""STRATEGIC CONSIDERATIONS IN DEVELOPING ANTIBODY-BASED THERAPIES FOR INFECTIOUS DISEASES""; ""EXAMPLES OF ANTIBODIES THAT ARE OR WERE IN DEVELOPMENT FOR INFECTIOUS DISEASES""; ""FUTURE PERSPECTIVES FOR ANTIBODY TREATMENTS IN INFECTIOUS DISEASES""; ""ACKNOWLEDGMENT""; ""CITATION"" 327 $a""REFERENCES""""GENERAL FEATURES OF IMMUNOGLOBULINS""; ""Chapter 2: Functions of Antibodies""; ""INTRODUCTION""; ""ANTIBODY FUNCTIONS INDEPENDENT OF EFFECTOR CELLS OR EFFECTOR MOLECULES""; ""INHIBITION OF LATER STEPS""; ""ANTIBODY FUNCTIONS DEPENDENT ON COMPLEMENT""; ""ANTIBODY FUNCTIONS DEPENDENT ON Fc-Fc RECEPTOR INTERACTIONS""; ""OTHER ANTIBODY FUNCTIONS""; ""CONCLUSIONS""; ""ACKNOWLEDGMENTS""; ""CITATION""; ""REFERENCES""; ""Chapter 3: Antibody Structure""; ""BASICS OF ANTIBODY STRUCTURE""; ""CDR H3: SIZE AND SUBTERFUGE""; ""HEAVY CHAIN DOMINATION AND FRAMEWORK CONTACTS"" 327 $a""DISULFIDES IN THE CDRs""""SELF-CARBOHYDRATE RECOGNITION: PENETRATING THE GLYCAN SHIELD""; ""UNUSUAL INDELS""; ""MECHANISMS OF ANTIBODY NEUTRALIZATION""; ""SUMMARY""; ""ACKNOWLEDGMENT""; ""CITATION""; ""REFERENCES""; ""Chapter 4: The Role of Complement in Antibody Therapy for Infectious Diseases""; ""INTRODUCTION""; ""COMPLEMENT ACTIVATION""; ""Ab-MEDIATED COMPLEMENT ACTIVATION""; ""EFFECTOR RESPONSES AND THEIR ROLE IN MAb TREATMENTS""; ""MANIPULATING Ab-MEDIATED COMPLEMENT RESPONSES""; ""COMPLEMENT EVASIVE PROPERTIES OF PATHOGENS""; ""CONCLUSIONS AND FUTURE PERSPECTIVE"" 327 $a""ACKNOWLEDGMENTS""""CITATION""; ""REFERENCES""; ""Chapter 5: Immunoglobulin E and Allergy: Antibodies in Immune Inflammation and Treatment""; ""IMMUNOLOGICAL MECHANISMS OF ALLERGIC DISEASES AND THE ROLE OF IgE ANTIBODIES""; ""IgE ANTIBODIES IN INFECTIOUS DISEASES""; ""ANTIBODIES IN THE TREATMENT OF ALLERGIES""; ""THE OPPOSITE SIDE OF THE COIN: HARNESSING THE ALLERGIC RESPONSE AGAINST CANCER AND THE EMERGENCE OF ANTIBODIES OF THE IgE CLASS FOR CANCER THERAPY""; ""CONCLUDING REMARKS AND FUTURE ROLES OF ANTIBODIES IN THERAPY""; ""ACKNOWLEDGMENTS""; ""CITATION""; ""REFERENCES"" 327 $a""ANTIBODY DISCOVERY APPROACHES""""Chapter 6: Phage and Yeast Display""; ""DISCOVERY OF THERAPEUTIC ANTIBODIES USING PHAGE DISPLAY TECHNOLOGY""; ""DISCOVERY OF THERAPEUTIC ANTIBODIES USING YEAST DISPLAY TECHNOLOGY""; ""CONCLUSIONS""; ""ACKNOWLEDGMENT""; ""CITATION""; ""REFERENCES""; ""Chapter 7: Efficient Methods To Isolate Human Monoclonal Antibodies from Memory B Cells and Plasma Cells""; ""MANY WAYS TO MAKE HUMAN MONOCLONAL ANTIBODIES""; ""EFFICIENT IMMORTALIZATION OF MEMORY B CELLS BY USING EBV AND CpG"" 327 $a""LONG-TERM CULTURE OF SINGLE PLASMA CELLS AND THEIR INTERROGATION USING MULTIPLE ASSAYS"" 606 $aImmunoglobulins 606 $aCommunicable diseases$xImmunological aspects 615 0$aImmunoglobulins. 615 0$aCommunicable diseases$xImmunological aspects. 676 $a616.0798 702 $aCrowe$b James E. Jr. 702 $aBoraschi$b D$g(Diana), 702 $aRappuoli$b Rino 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830911403321 996 $aAntibodies for infectious diseases$94052555 997 $aUNINA